EGFR and lung cancer: Previous animal and cell line studies along with analysis of human datasets have shown that A3B overexpression drives drug resistance and tumour evolvability in various human malignancies, including oestrogen receptor‐positive breast tumours24 and EGFR‐ and ALK‐driven lung cancer.27